Magnesium isoglycyrrhizinate versus compound glycyrrhizin in treatment of patients with non-alcoholic fatty liver disease

  Objective  To compare the efficacy and safety of magnesium isoglycyrrhizinate and compound glycyrrhizin in the treatment of patients with non-alcoholic fatty liver disease (NAFLD).

  Methods   Totally 60 patients with NAFLD were divided into control group and observation group according to therapeutic methods, with 30 cases in each group. Patients in the control group were treated with compound glycyrrhizin, and those in the observation group were treated with magnesium isoglycyrrhizinate. The liver function indexes, blood lipid indexes, magnesium ions level, improvement of clinical symptoms, efficacy and adverse reactions were compared between two groups.

  Results   The total effective rate of the observation group was 96.67%, which was significantly higher than 80.00% of the control group (P < 0.05). The levels of glutamic pyruvate transaminase, aspartate transaminase, total cholesterol and triglyceride after treatment in the observation group were significantly lower than those in the control group (P < 0.05). No severe adverse reactions were observed in both groups.

  Conclusion   Magnesium isoglycyrrhizinate can significantly improve liver function and blood lipid indexes of patients with NAFLD, and its safety is high.